Chapter 20: Antiepileptic Drugs

Antiepileptic Drugs categorizes seizures into focal episodes, which are localized to one brain hemisphere, and generalized episodes, such as tonic-clonic and absence seizures, which involve bilateral brain activity and loss of consciousness. The underlying neurobiology of these events is attributed to excessive excitatory neurotransmission, primarily mediated by glutamate, or a deficiency in the inhibitory signaling of gamma-aminobutyric acid (GABA). To counteract these imbalances, antiepileptic medications employ several key mechanisms: inhibiting voltage-gated sodium or calcium channels to stabilize hyper-excitable membranes, augmenting GABAergic inhibition, or blocking excitatory glutamate receptors. Classic agents such as carbamazepine and phenytoin remain first-line treatments for many focal and tonic-clonic seizures by prolonging the inactive state of sodium channels, though they require careful monitoring due to their role as potent cytochrome P450 enzyme inducers. Valproate is highlighted for its broad-spectrum utility across various seizure types, whereas ethosuximide is identified as the gold standard for treating childhood absence seizures by targeting T-type calcium channels in the thalamus. The text also details the emergency management of status epilepticus, a life-threatening condition requiring rapid intervention with intravenous benzodiazepines like diazepam or lorazepam. Furthermore, it addresses newer therapeutic options, including levetiracetam, topiramate, and the first-of-its-kind cannabinoid drug, cannabidiol, for refractory pediatric syndromes like Lennox-Gastaut and Dravet syndrome. Clinical considerations, such as the preference for monotherapy, the risk of teratogenicity, and the necessity of gradual drug tapering to avoid rebound seizures, are emphasized to ensure optimal patient outcomes and safety.